Skip to main content
NVDA-1.77%AAPL+1.04%GOOGL+0.03%MSFT-0.73%AMZN-0.88%TSM-1.73%SPCX-2.00%META-2.18%AVGO-1.77%TSLA-2.32%LLY+3.82%BRK-B-0.18%SKHY-3.36%MU-0.76%AMD-3.48%WMT+1.59%JPM+0.63%V-0.68%XOM+0.79%ASMLa+2.21%JNJ+1.05%MA-0.30%INTC-2.36%ABBV+3.01%0700.HK-0.42%1398.HK-0.92%CSCO+0.86%CVX+1.02%COST+1.27%KO+0.54%ORCL-7.42%PG+1.09%LRCX-2.42%AMAT-1.63%AP2d+0.82%UNH+2.98%BAC-8.20%DELL-7.18%CAT-0.98%1816.HK+2.71%3988.HK-1.12%0005.HK-1.79%0857.HK+1.17%HSBA.L-1.48%GE+0.68%PM+1.36%0939.HK-1.00%1288.HK-2.23%NFLX-0.30%HD-1.40%USDMXN+1.07%USDSEK+1.02%USDCHF+0.97%USDZAR+0.79%CADCHF+0.75%EURUSD-0.71%AUDCHF+0.69%USDPLN+0.69%USDDKK+0.69%EURHKD-0.67%NZDUSD-0.64%CHFJPY-0.62%EURCNH-0.58%GBPCHF+0.52%USDTHB+0.51%EURCAD-0.50%USDSGD+0.50%NZDCAD-0.45%GBPUSD-0.45%USDNOK+0.44%EURAUD-0.42%GBPTRY+0.41%AUDNZD+0.40%AUDDKK+0.40%NZDMXN+0.39%EURJPY-0.37%PLNJPY-0.36%CHFSEK+0.35%EURSEK+0.34%NZDJPY-0.33%USDJPY+0.33%GBPHKD+0.32%NZDCHF+0.29%GBPMXN-0.28%USDTRY+0.28%AUDUSD-0.27%EURCHF+0.25%EURGBP-0.24%EURNOK-0.23%CHFNOK-0.22%USDCAD+0.22%AUDSGD+0.22%GBPCAD-0.22%GBPNZD+0.19%NZDSGD-0.18%SGDJPY-0.18%EURSGD-0.17%GBPZAR+0.17%GBPAUD-0.17%AUDNOK+0.16%USDILS+0.16%CHFSGD-0.16%GBPJPY-0.13%NOKJPY-0.12%GBPSGD-0.12%EURZAR+0.11%CADJPY+0.10%USDCNH+0.09%AUDJPY+0.05%EURCZK+0.05%AUDCAD-0.05%USDCOP-0.04%EURNZD-0.02%EURPLN+0.01%USDHKD+0.01%EURDKK+0.01%XAGUSD-4.97%GAGUSD-4.96%COFFEE+2.68%XPTUSD-2.56%XNGUSD-2.45%GAUUSD-1.57%XAUUSD-1.57%SUGAR-1.09%COTTON+0.59%COCOA+0.54%S1-0.50%USOIL+0.48%BTCUSD-1.26%ETHUSD+15.24%USDTUSD0.00%XRPUSD+9.86%SOLUSD+10.90%TRXUSDT+1.94%ZECUSDT-2.83%DOGEUSD+11.12%XMRUSDT+0.46%LINKUSD+11.09%XLMUSD-3.45%BCHUSDT-1.32%UNIUSD-4.74%LTCUSD+9.37%SUIUSD-3.19%HBARUSDT-3.32%TONUSD+24.80%TAOUSDT-3.13%AAVEUSD-2.62%DOTUSDT-2.95%ICPUSDT-3.53%ONDOUSDT-4.12%WLDUSDT-5.20%ARBUSDT-5.01%JUPUSDT-4.37%ATOMUSDT-4.85%INJUSDT-3.92%STXUSDT-2.86%FETUSDT-3.27%PYTHUSDT+5.88%TIAUSDT-5.79%SEIUSDT-3.09%IMXUSDT-5.36%OPUSDT-10.56%GRTUSDT-3.67%WIFUSDT-3.70%IOTAUSDT-5.42%AXSUSDT-4.44%POLUSDT-4.81%EOSUSDT+4.19%FARTCOINUSDT-5.61%DYDXUSDT-5.85%GALAUSDT-5.44%ORDIUSDT-4.44%RONINUSDT-7.27%NOTUSDT-5.58%NVDA-1.77%AAPL+1.04%GOOGL+0.03%MSFT-0.73%AMZN-0.88%TSM-1.73%SPCX-2.00%META-2.18%AVGO-1.77%TSLA-2.32%LLY+3.82%BRK-B-0.18%SKHY-3.36%MU-0.76%AMD-3.48%WMT+1.59%JPM+0.63%V-0.68%XOM+0.79%ASMLa+2.21%JNJ+1.05%MA-0.30%INTC-2.36%ABBV+3.01%0700.HK-0.42%1398.HK-0.92%CSCO+0.86%CVX+1.02%COST+1.27%KO+0.54%ORCL-7.42%PG+1.09%LRCX-2.42%AMAT-1.63%AP2d+0.82%UNH+2.98%BAC-8.20%DELL-7.18%CAT-0.98%1816.HK+2.71%3988.HK-1.12%0005.HK-1.79%0857.HK+1.17%HSBA.L-1.48%GE+0.68%PM+1.36%0939.HK-1.00%1288.HK-2.23%NFLX-0.30%HD-1.40%USDMXN+1.07%USDSEK+1.02%USDCHF+0.97%USDZAR+0.79%CADCHF+0.75%EURUSD-0.71%AUDCHF+0.69%USDPLN+0.69%USDDKK+0.69%EURHKD-0.67%NZDUSD-0.64%CHFJPY-0.62%EURCNH-0.58%GBPCHF+0.52%USDTHB+0.51%EURCAD-0.50%USDSGD+0.50%NZDCAD-0.45%GBPUSD-0.45%USDNOK+0.44%EURAUD-0.42%GBPTRY+0.41%AUDNZD+0.40%AUDDKK+0.40%NZDMXN+0.39%EURJPY-0.37%PLNJPY-0.36%CHFSEK+0.35%EURSEK+0.34%NZDJPY-0.33%USDJPY+0.33%GBPHKD+0.32%NZDCHF+0.29%GBPMXN-0.28%USDTRY+0.28%AUDUSD-0.27%EURCHF+0.25%EURGBP-0.24%EURNOK-0.23%CHFNOK-0.22%USDCAD+0.22%AUDSGD+0.22%GBPCAD-0.22%GBPNZD+0.19%NZDSGD-0.18%SGDJPY-0.18%EURSGD-0.17%GBPZAR+0.17%GBPAUD-0.17%AUDNOK+0.16%USDILS+0.16%CHFSGD-0.16%GBPJPY-0.13%NOKJPY-0.12%GBPSGD-0.12%EURZAR+0.11%CADJPY+0.10%USDCNH+0.09%AUDJPY+0.05%EURCZK+0.05%AUDCAD-0.05%USDCOP-0.04%EURNZD-0.02%EURPLN+0.01%USDHKD+0.01%EURDKK+0.01%XAGUSD-4.97%GAGUSD-4.96%COFFEE+2.68%XPTUSD-2.56%XNGUSD-2.45%GAUUSD-1.57%XAUUSD-1.57%SUGAR-1.09%COTTON+0.59%COCOA+0.54%S1-0.50%USOIL+0.48%BTCUSD-1.26%ETHUSD+15.24%USDTUSD0.00%XRPUSD+9.86%SOLUSD+10.90%TRXUSDT+1.94%ZECUSDT-2.83%DOGEUSD+11.12%XMRUSDT+0.46%LINKUSD+11.09%XLMUSD-3.45%BCHUSDT-1.32%UNIUSD-4.74%LTCUSD+9.37%SUIUSD-3.19%HBARUSDT-3.32%TONUSD+24.80%TAOUSDT-3.13%AAVEUSD-2.62%DOTUSDT-2.95%ICPUSDT-3.53%ONDOUSDT-4.12%WLDUSDT-5.20%ARBUSDT-5.01%JUPUSDT-4.37%ATOMUSDT-4.85%INJUSDT-3.92%STXUSDT-2.86%FETUSDT-3.27%PYTHUSDT+5.88%TIAUSDT-5.79%SEIUSDT-3.09%IMXUSDT-5.36%OPUSDT-10.56%GRTUSDT-3.67%WIFUSDT-3.70%IOTAUSDT-5.42%AXSUSDT-4.44%POLUSDT-4.81%EOSUSDT+4.19%FARTCOINUSDT-5.61%DYDXUSDT-5.85%GALAUSDT-5.44%ORDIUSDT-4.44%RONINUSDT-7.27%NOTUSDT-5.58%
ST

Sarepta Therapeutics, Inc. (SRPT)

NASDAQ • Healthcare

$16.51
-$0.92 (-5.3%)
Market open

Last close at October 13, 2026 at 20:00 UTC

Open$17.12
Previous Close$16.51
Day Range$16.41 - $17.23
Avg. Volume (3M)2.7M
Market Cap$1.7B
52 Week Range
$14.68$24.68
Next EarningsIn 21 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$401.2M100%
Gross Profitminus cost of goods$251.8M63%
Operating Incomeminus R&D and overhead$13.2M3%

In plain terms: out of every $100 in revenue, Sarepta Therapeutics, Inc. currently loses $1.

Fundamentals & Financials

Revenue (TTM)
$1.9B
Net Income (TTM)
-$136.7M
EPS (TTM)
-$1.44
ROA (TTM)
-4.29%
Current Ratio
4.42

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-247.6%Q1 2026-$3.58
+223.8%Q2 2026$3.16
-123.0%Q3 2026-$0.05
Next

Nov 4

in 21 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -123.0%

Sarepta Therapeutics beat consensus on both revenue and adjusted EPS in the second fiscal quarter of 2026, reported Aug. 5, based on preliminary results. Revenue came in at about $401.3 million, down 34% from $611.1 million a year ago but about 10% above the $366.4 million estimate, while adjusted EPS was $0.64 versus $0.22 expected, about +195%, even as it fell 68% from $2.02 a year earlier. Gross profit reached about $251.9 million, and the 62.8% gross margin left operating margin near 3% as operating income landed at about $13.3 million. Operating cash flow was negative about $5.6 million.

Next report — what to expect

Sarepta Therapeutics, Inc. (SRPT) is set to report earnings on November 4, 2026. Wall Street’s next-period consensus calls for EPS of $0.136 on revenue of $353.8 million. For trailing context, revenue fell -34.3% year over year last quarter. Sarepta has beaten EPS in 4 of 8 most recent quarters.

View full earnings history

About Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. develops genetic medicines for rare diseases and operates in biotechnology within the healthcare sector. Listed on NASDAQ as SRPT, the company combines commercial Duchenne muscular dystrophy therapies with a broader pipeline of RNA-targeted therapeutics and gene therapies, generating $2.2 billion of revenue in FY2025.

Name
Sarepta Therapeutics, Inc.
CEO
Michael E. Severino
Website
www.sarepta.com
Industry
Healthcare
Year Founded
1980
Employees
835

Today's Snapshot

AI-generated

SRPT closed 5.3% lower at 16.51.

Trading Volume

Above 10d avg 2.9M

3.6M

vs S&P 500 Today

Strong Underperformance

-5.31%

Updated: October 14, 2026 at 12:30 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
SRPT is trading at 16.51 and reflects a bearish technical posture, with price beneath short-, medium- and longer-term moving averages and the classic pivot at 17.63 overhead as resistance. Momentum and trend measures are weak — MACD and CCI signal downside and RSI sits toward lower levels — while ADX near 18 indicates limited trend strength. Volatility is relatively high with ATR around 6.0%, and on‑balance volume is consistent with selling pressure. Collectively these indicators support the negative bias. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$17.69 - $19.27
    Sell
  • RSI (14)34.78
    Neutral
  • Stochastic %K (14, 3, 3)12.17
    Buy
  • MACD Level (12, 26)-0.68
    Sell

Peers & Related Assets

ALNYAlnylam Pharmaceuticals, Inc.
$223.82-1.4%
IONSIonis Pharmaceuticals, Inc.
$42.38-3.0%
PTCTPTC Therapeutics, Inc.
$59.92-4.8%
DYNDyne Therapeutics, Inc.
$15.3-4.1%
NTLAIntellia Therapeutics, Inc.
$11.91-5.3%
DSGNDesign Therapeutics, Inc.
$9.78-10.4%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.